Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are often recognized for the dramatic skin blistering and detachment that occur during the acute illness. But a new systematic review published September 5, 2026, reinforces an equally important point: SJS/TEN can affect multiple organ systems and leave survivors with lasting complications that extend far beyond the skin.
For patients, families, and lawyers evaluating a potential medication-induced SJS/TEN claim, that matters. A case should not be assessed solely by the amount of skin detachment during the hospitalization. Long-term eye, lung, genitourinary, ear-nose-throat, gastrointestinal, and other complications may materially affect medical needs, functional loss, quality of life, and damages.
What the 2026 Review Found
The review, published in Clinical, Cosmetic and Investigational Dermatology, examined 38 articles published between 2019 and 2024 that reported multiorgan complications in patients with SJS/TEN. The included literature consisted of reviews, original studies, case reports, and case series. Because of that heterogeneity, the authors appropriately cautioned that the percentages reported in the review reflect how often complications appeared across the included studies, not true patient-level prevalence rates.
Even with that limitation, the pattern was clear. Ocular involvement was the most frequently reported category, appearing in 65.8% of the included studies. Pulmonary and genitourinary complications were each reported in 26.32% of studies, while skin-related chronic complications were reported in 21.05%. The review also described complications involving the ear, nose and throat, gastrointestinal tract, and other systems.
Among studies reporting ocular injury, trichiasis, distichiasis, and symblepharon were among the most commonly described chronic problems. These conditions can cause persistent irritation, pain, scarring, visual impairment, and the need for repeated specialist care or surgery.
Why SJS/TEN Is Not Just a Skin Disease
SJS/TEN is a severe immune-mediated reaction, most often triggered by medication. The same inflammatory process that damages the epidermis can also injure mucosal surfaces and internal organs. During the acute phase, patients may require intensive care, burn-unit management, ophthalmology, gynecology or urology, pulmonology, otolaryngology, and other specialty services.
The long-term consequences can be substantial. Ocular scarring may produce chronic dry eye, corneal injury, eyelid abnormalities, or vision loss. Pulmonary injury may include chronic airway disease or, in rare cases, bronchiolitis obliterans. Genitourinary mucosal injury can lead to scarring, stenosis, pain, sexual dysfunction, and other chronic problems. Persistent skin changes, nail abnormalities, oral complications, and psychological effects may continue well after discharge.
Why These Findings Matter in an SJS/TEN Case Evaluation
From a legal perspective, the new review does not create a new liability theory and does not prove that any particular medication caused a patient's reaction. Drug causation still requires careful analysis of medication timing, known drug associations, alternative causes, medical records, and the clinical course. Product-liability issues also depend on the specific drug, manufacturer, labeling in effect at the time of exposure, prescribing history, and jurisdiction.
What the review does strengthen is the medical basis for looking comprehensively at injury and damages. A patient who survives the acute hospitalization may still face years of specialist care, procedures, medications, functional limitations, lost earning capacity, and diminished quality of life. Those consequences can be missed if a case review focuses only on the initial dermatologic presentation.
For that reason, a thorough SJS/TEN intake should ask about ophthalmology follow-up, chronic eye pain or vision changes, respiratory symptoms, genitourinary symptoms, swallowing or voice problems, ongoing skin or nail changes, mental-health effects, and later surgeries or procedures. Long-term medical records can be as important as the original hospitalization records when evaluating the full extent of injury.
California Cases Require Careful Exposure and Warning Analysis
California can present important issues in pharmaceutical cases, particularly when a patient received a generic version of a medication. California decisions have recognized certain negligent-misrepresentation theories involving brand-name labeling even when the patient ultimately took a generic product, but those theories are fact-dependent and do not eliminate the need to prove reliance, causation, warning inadequacy, and other elements. Generic-drug preemption can also sharply limit claims against generic manufacturers themselves.
Accordingly, the first steps in any potential California SJS/TEN matter should include identifying every suspected drug, determining whether the product was brand or generic, obtaining pharmacy dispensing records, preserving the exact prescribing information and warnings in effect during the exposure period, and documenting the timing of symptoms and every subsequent complication.
What Patients and Families Should Preserve
- Hospital, burn-unit, dermatology, ophthalmology, pulmonary, ENT, gynecology/urology, and follow-up records.
- Pharmacy records identifying the exact drug, manufacturer, dosage, refill dates, and National Drug Code when available.
- Photographs from the acute hospitalization and recovery period.
- Records of later procedures, surgeries, vision treatment, respiratory care, rehabilitation, and counseling.
- Documentation of work loss, disability, caregiving needs, and out-of-pocket medical expenses.
The Bottom Line
The September 2026 systematic review adds useful contemporary support for what experienced SJS/TEN clinicians and survivors have long understood: the disease can produce serious, multisystem consequences that persist long after the skin heals. For case evaluation, the practical lesson is simple. Identifying the causative medication is only one part of the analysis; documenting the complete long-term injury is equally important.
Greg Jones Law has decades of experience evaluating medication-induced SJS/TEN cases. Every potential case turns on its individual medical history, drug exposure, warning history, jurisdiction, and timing.
Sources
Firdaus CP, et al. The Multiorgan Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review. Clinical, Cosmetic and Investigational Dermatology. Published September 5, 2026. DOI: 10.2147/CCID.S626838. https://www.dovepress.com/the-multiorgan-complications-of-stevens-johnson-syndrome-and-toxic-epi-peer-reviewed-fulltext-article-CCID
Shanbhag SS, et al. Multidisciplinary care in Stevens-Johnson syndrome. Therapeutic Advances in Chronic Disease. 2020;11:2040622319894469. DOI: 10.1177/2040622319894469. https://doi.org/10.1177/2040622319894469
Conte v. Wyeth, Inc., 168 Cal.App.4th 89 (2008). https://law.justia.com/cases/california/court-of-appeal/2008/a116707/
T.H. v. Novartis Pharmaceuticals Corp., 4 Cal.5th 145 (2017/official opinion history reflected in current California case databases). https://law.justia.com/cases/california/supreme-court/2021/s233898.html